Heart Failure with Normal Ejection Fraction Heart Failure with Preserved Ejection Fraction
Conditions
Interventions
None listed
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients 18 years of age or older Able and willing to provide freely given written informed consent including analysis of genomics. Signs or symptoms of Heart Failure, preserved LVEF (>50%) and evidence of diastolic dysfunction: ;The ratio of early mitral valve flow velocity (E) and early TD lengthening velocity (E*), E/E*>15. In the case that E/E* ratio is only suggestive of diastolic LV dysfunction (15>E/E*>8), additional non-invasive measures are required for the diagnosis of LV diastolic dysfunction. These consist of: • Plasma levels of natriuretic peptides (NT-proBNP> 220 pg/mL or BNP > 200 pg/mL) OR • Echo - blood flow Doppler of mitral valve - ratio of early (E) to late (A) mitral valve flow velocity (E/A) 280 ms OR • Echo- blood flow Doppler of pulmonary veins - duration of reverse pulmonary vein atrial systole flow (Ard) and duration of mitral valve atrial wave flow (Ad) (Ard-Ad >30ms) OF • Echo measure of left atrial volume index (LAVI) > 34 mL/m2 OR • Echo measure of left ventricular max index (LVMI)> 109 g/m2 for women; 132 g/m2 for men) OR • Electrocardiografic evidence of atrial fibrillation
Exclusion criteria
Exclusion criteria: Patients with acute myocardial infarction Recent trauma or surgery (
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the specificity and the sensitivity of biomarkers for the diagnosis of DHF. | — |
Secondary
| Measure | Time frame |
|---|---|
| The prognostic power of biomarkers relative to all-cause death, cardiovascular hospitalization, death or cardiovascular hospitalization. | — |
Countries
Netherlands
Outcome results
None listed